The Global Health Body Sounds Concern Over Critical Lack of Weight-Loss Jabs

Fewer than a tenth of individuals that would benefit from obesity jabs such as Wegovy have access to them, caution the WHO as it publishes its inaugural guidance on the drugs.

Given over a billion individuals worldwide currently obese, it is calling for increased and just access to this class of drugs.

According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.

"Our new guidance recognises that excess weight is a lifelong illness that can be treated with thorough and ongoing support," said its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and logistical bottlenecks are major hurdles to broad availability to the jabs that can aid individuals in losing significant weight, notes the agency.

Skinny Jab Scarcity

Even in the present best projected case, the production of such drugs could only cover approximately 100 million people – fewer than 10% of eligible patients, according to the health organization.

The recommendation urges nations and manufacturers to increase availability, via strategies like voluntary licensing.

Exclusive production rights on semaglutide – the core ingredient of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.

The Way Weight-Loss Jabs Work

These medications replicate a body's own hormone to reduce digestion speed, curb appetite and increase satiety so people reduce food intake.

Patients typically see weight reduction in the initial weeks of beginning the weekly injections.

Research indicates users may see weight return after a year of discontinuing the drug, because their usual appetite resume.

To be carrying excess weight elevates your likelihood for developing diseases, including type 2 diabetes, cardiovascular issues, stroke, and specific cancers.

Obesity affects individuals in all nations and was associated with millions of deaths worldwide in 2024, per the WHO.